A Novel Therapeutic Strategy to Eradicate HIV-1 Infection

Antibodies and the complement system work together to specifically detect and clear viruses, but they are circumvented by HIV, which hides itself and the cells it infects by hijacking host proteins such as CD59. Qigui Yu of Indiana University School of Medicine in U.S. will attempt to unmask HIV and HIV-infected cells and render them susceptible to antibody-complement attack. In this project’s Phase I research, Yu and his team identified a potent, specific, and non-toxic inhibitor of human CD59, which is used by HIV to escape destruction by antibody-complement attack. In Phase II, Yu will continue to research how this inhibitor might allow antibodies to regain their complement-mediated activity to destroy the virus and HIV-infected cells, and will also research how HIV-1 incorporates human CD59 onto viral particles to escape antibody-complement immunity.

Grant ID
OPP1035237
Show on Hub
Off
Show on Spoke
Off
Follow-on Funding
Off
Lead Funding Organization
Principal Investigator
Individual Funder Information
Funding Organization
Funding Amount (in original currency)
489506.00
Funding Currency
USD
Funding Amount (in USD)
489506.00
Project Type
Project Primary Sector
Project Subsector
Funding Date Range
-
Funding Total (In US dollars)
489506.00
Co-Funded
False